Data as of Mar 11
| +0.02 / +0.53%|
The 4 analysts offering 12-month price forecasts for Cell Therapeutics Inc have a median target of 4.00, with a high estimate of 7.00 and a low estimate of 3.53. The median estimate represents a +5.54% increase from the last price of 3.79.
The current consensus among 4 polled investment analysts is to Buy stock in Cell Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.